PriceTargets.com logo

Zentalis Pharmaceuticals - ZNTL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.00
  • Forecasted Upside: 233.33%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.00 As of 12/20/2024 06:17 PM ET
▲ +0.07 (2.39%)

This chart shows the closing price for ZNTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zentalis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZNTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZNTL

Analyst Price Target is $10.00
▲ +233.33% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Zentalis Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $20.00 and a low forecast of $4.00. The average price target represents a 233.33% upside from the last price of $3.00.

This chart shows the closing price for ZNTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Zentalis Pharmaceuticals. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024GuggenheimLower TargetBuy ➝ Buy$12.00 ➝ $8.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
9/16/2024OppenheimerReiterated RatingOutperform ➝ Outperform$20.00 ➝ $20.00
8/12/2024WedbushUpgradeUnderperform ➝ Neutral$4.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
6/20/2024UBS GroupDowngradeBuy ➝ Neutral$28.00 ➝ $5.00
6/18/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$42.00 ➝ $6.00
6/18/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $8.00
6/18/2024OppenheimerLower TargetOutperform ➝ Outperform$50.00 ➝ $25.00
6/18/2024HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $20.00
6/18/2024Stifel NicolausLower TargetBuy ➝ Buy$32.00 ➝ $10.00
6/18/2024WedbushDowngradeNeutral ➝ Underperform$15.00 ➝ $4.00
6/18/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$29.00 ➝ $9.00
5/8/2024HC WainwrightLower TargetBuy ➝ Buy$46.00 ➝ $40.00
5/8/2024Stifel NicolausLower TargetBuy ➝ Buy$36.00 ➝ $32.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$46.00
2/28/2024WedbushBoost TargetNeutral ➝ Neutral$12.00 ➝ $15.00
11/8/2023WedbushDowngradeOutperform ➝ Neutral$38.00 ➝ $12.00
11/7/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
11/7/2023Stifel NicolausLower TargetBuy ➝ Buy$44.00 ➝ $36.00
11/7/2023Morgan StanleyLower TargetOverweight ➝ Overweight$55.00 ➝ $38.00
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$55.00 ➝ $46.00
11/7/2023Leerink PartnersDowngradeOutperform ➝ Market Perform$15.00
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$38.00
8/10/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$51.00 ➝ $50.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$55.00
6/7/2023Stifel NicolausBoost Target$45.00 ➝ $50.00
5/26/2023WedbushBoost Target$31.00 ➝ $38.00
5/19/2023Jefferies Financial GroupLower Target$120.00 ➝ $70.00
5/11/2023Stifel NicolausLower Target$46.00 ➝ $45.00
3/15/2023Stifel NicolausLower Target$55.00 ➝ $46.00
3/2/2023HC WainwrightReiterated RatingBuy$55.00
11/21/2022UBS GroupLower Target$52.00
11/14/2022WedbushLower TargetOutperform$51.00 ➝ $32.00
11/14/2022Wells Fargo & CompanyLower Target$52.00 ➝ $46.00
11/11/2022GuggenheimLower TargetBuy$55.00 ➝ $28.00
11/11/2022Morgan StanleyLower TargetOverweight$60.00 ➝ $55.00
11/10/2022Leerink PartnersLower TargetOutperform$42.00 ➝ $27.00
11/10/2022OppenheimerLower TargetOutperform$80.00 ➝ $50.00
8/11/2022Morgan StanleyLower TargetOverweight$95.00 ➝ $60.00
8/10/2022Leerink PartnersLower TargetOutperform$67.00 ➝ $42.00
8/10/2022HC WainwrightLower TargetBuy$120.00 ➝ $55.00
7/12/2022CowenInitiated CoverageOutperform
7/12/2022CowenInitiated CoverageOutperform
5/17/2022GuggenheimLower TargetNA$57.00
5/10/2022WedbushLower TargetOutperform$71.00 ➝ $51.00
4/13/2022GuggenheimLower Target$92.00 ➝ $67.00
4/12/2022OppenheimerLower TargetOutperform$100.00 ➝ $85.00
4/12/2022Leerink PartnersLower TargetOutperform$78.00 ➝ $67.00
4/11/2022Stifel NicolausLower Target$94.00 ➝ $74.00
4/6/2022Wells Fargo & CompanyInitiated CoverageOverweight$67.00
2/25/2022WedbushReiterated RatingOutperform
12/17/2021Leerink PartnersBoost TargetOutperform$89.00 ➝ $97.00
12/10/2021Leerink PartnersBoost TargetOutperform$84.00 ➝ $89.00
11/11/2021WedbushReiterated RatingOutperform$89.00
11/11/2021HC WainwrightBoost TargetBuy$80.00 ➝ $120.00
10/28/2021Leerink PartnersBoost TargetOutperform$64.00 ➝ $84.00
10/27/2021WedbushBoost TargetOutperform$65.00 ➝ $89.00
9/29/2021Stifel NicolausInitiated CoverageBuy$84.00
9/28/2021OppenheimerInitiated CoverageOutperform$90.00
5/20/2021UBS GroupInitiated CoverageBuy$91.00
5/19/2021HC WainwrightBoost TargetPositive ➝ Buy$65.00 ➝ $80.00
4/19/2021Leerink PartnersBoost TargetOutperform$60.00 ➝ $64.00
4/12/2021Leerink PartnersBoost TargetOutperform$44.00 ➝ $60.00
3/26/2021HC WainwrightBoost TargetBuy$43.00 ➝ $65.00
1/19/2021WedbushInitiated CoverageOutperform$65.00
12/16/2020Morgan StanleyBoost TargetOverweight$50.00 ➝ $75.00
11/11/2020Morgan StanleyBoost TargetOverweight$49.00 ➝ $50.00
9/28/2020Cantor FitzgeraldInitiated CoverageOverweight$44.00
8/27/2020HC WainwrightInitiated CoverageBuy$43.00
8/24/2020Morgan StanleyBoost TargetOverweight$45.00 ➝ $49.00
7/28/2020Leerink PartnersReiterated RatingBuy
5/12/2020Morgan StanleyReiterated RatingOverweight$45.00
4/28/2020Morgan StanleyInitiated CoverageOverweight$45.00
4/28/2020Leerink PartnersInitiated CoverageOutperform$45.00
4/28/2020GuggenheimInitiated CoverageBuy$45.00
4/28/2020Jefferies Financial GroupInitiated CoverageBuy$41.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Zentalis Pharmaceuticals logo
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Read More

Today's Range

Now: $3.00
Low: $2.89
High: $3.10

50 Day Range

MA: $3.32
Low: $2.70
High: $4.03

52 Week Range

Now: $3.00
Low: $2.66
High: $18.07

Volume

1,850,707 shs

Average Volume

1,306,717 shs

Market Capitalization

$213.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Zentalis Pharmaceuticals?

The following Wall Street research analysts have issued reports on Zentalis Pharmaceuticals in the last year: Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Stifel Nicolaus, UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ZNTL.

What is the current price target for Zentalis Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Zentalis Pharmaceuticals in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 233.3%. Oppenheimer Holdings Inc. has the highest price target set, predicting ZNTL will reach $20.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $4.00 for Zentalis Pharmaceuticals in the next year.
View the latest price targets for ZNTL.

What is the current consensus analyst rating for Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ZNTL, but not buy more shares or sell existing shares.
View the latest ratings for ZNTL.

What other companies compete with Zentalis Pharmaceuticals?

Other companies that are similar to Zentalis Pharmaceuticals include Nuvation Bio, ArriVent BioPharma, Immatics, Replimune Group and uniQure. Learn More about companies similar to Zentalis Pharmaceuticals.

How do I contact Zentalis Pharmaceuticals' investor relations team?

Zentalis Pharmaceuticals' physical mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The company's listed phone number is 212-433-3791 and its investor relations email address is [email protected]. The official website for Zentalis Pharmaceuticals is www.zentalis.com. Learn More about contacing Zentalis Pharmaceuticals investor relations.